All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Ipsen Biopharmaceuticals, Lilly, and Pfizer. View funders.
Bookmark this article
Since the first cases of coronavirus disease 2019 (COVID-19) were reported in December 2019, more than 3 million people have died of the disease worldwide. Disease severity varies widely, with certain factors (including age and certain comorbidities) conferring a worse prognosis. Patients with hematologic malignancies generally have more severe disease with higher mortality rates compared to the general population: a meta-analysis of 3,240 adult patients with hematologic malignancies reported a 34% risk of death associated with COVID-19.1 This is multifactorial but is thought to be due largely to impaired humoral immune response due to both the underlying malignancy and anticancer therapy.
Following is a summary of recent data from published studies as well as from abstracts presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition regarding COVID-19 severity, mortality, and mRNA vaccine responses in patients with chronic lymphocytic leukemia (CLL).
Patients with CLL are likely to be more susceptible to severe COVID-19 and increased risk of death associated with COVID-19 due to age, disease, and impaired immune function. Chatzikonstantinou, et al. recently published in Leukemia a retrospective review of data from the European Research Initiative on CLL (ERIC) and Campus CLL to determine severity and mortality of COVID-19 in patients with CLL.2
Data were collected from 91 centers from the beginning of the pandemic until March 16, 2021, and case fatality rate, disease severity, and overall survival (OS) were analyzed. The OS analysis was limited to patients with severe COVID-19 (defined by hospitalization and requirement of supplemental oxygen or admission into an intensive care unit).2
Most patients were diagnosed with CLL (94.3%; Table 1) and had a median of two comorbidities, with a median age of 69 years. Most patients were treated with Bruton’s tyrosine kinase (BTK) inhibitors (56.3%), venetoclax monotherapy (10.7%), or chemoimmunotherapy (9.1%).
Table 1. Patient Characteristics*
Patient characteristics, % (unless otherwise stated) |
Results |
---|---|
Age at COVID-19 (median, IQR), years |
69 (61–77) |
Male |
66.7 |
Diagnosis |
|
CLL |
94.3 |
MBL |
1.7 |
SLL |
4 |
Obesity (BMI >30) |
17.3 |
Smoking |
|
Current smoker |
8.8 |
Ex-smoker |
26.8 |
Never smoker |
64.4 |
Hypogammaglobulinemia (IgG <550 mg/dL) |
49.5
|
CIRS score (range) |
0–32 |
N of comorbidities (median, range), n |
2 (0–11) |
Other respiratory |
6.5 |
Asthma |
2.2 |
COPD |
6.5 |
Cardiac Failure |
3.2 |
Arrythmias |
9.3 |
Coronary artery disease |
10 |
Other cardiovascular |
8.9 |
Hypertension |
47 |
Diabetes |
18.5 |
Chronic renal disease |
5.4 |
Other hematologic malignancies |
1.1 |
Other non-hematologic malignancies (excluding skin) |
8 |
CIRS, cumulative illness rating scale; COPD, chronic obstructive pulmonary disease; CLL, chronic lymphocytic leukemia; IQR, interquartile range; MBL, monoclonal B lymphocytosis; SLL, small lymphocytic lymphoma. |
The case fatality rate in patients with severe COVID-19 was 38.4%, and untreated patients had a greater OS than those on treatment or recently treated (hazard ratio [HR], 0.54; 95% confidence interval [CI], 0.41–0.72; p < 0.001). The authors also assessed the impact of specific treatments on COVID-19 outcome in two comparisons:
On multivariate analysis, statistically significant risk factors for mortality included older age (p < 0.001), cardiac failure (p = 0.035), and treatment status (p < 0.001) (Table 2).
A subanalysis of patients with severe COVID-19 found age ≥75 (compared with age <75, p < 0.001) and CLL treatment status (treated vs untreated, p < 0.001; treated at the time of COVID-19 infection vs untreated, p < 0.001; treated in the last 12 months yes vs no, p = 0.002) to be the most statistically significant risk factors of infection outcome in this population.
Table 2. Risk factors for OS*
Risk factor |
p value |
---|---|
Age (≥65 vs <65) |
0.01 |
Age (≥75 vs <75) |
<0.001 |
IGHV gene somatic hypermutation status (unmutated vs mutated) |
0.01 |
del(17p) (last assessment) (positive vs negative) |
0.02 |
CIRS score (> 6 vs ≤6) |
<0.001 |
Cardiac Failure (yes vs no) |
<0.001 |
Chronic renal disease (yes vs no) |
0.02 |
Hypogammaglobulinemia (IgG <550 mg/dL) (present vs absent) |
0.08 |
CLL treatment status (untreated vs treated) |
<0.001 |
CLL treatment during COVID-19 (treated vs untreated) |
<0.001 |
Treated in last 12 months (treated vs untreated) |
0.01 |
CIRS, cumulative illness rating scale; CLL, chronic lymphocytic leukemia; COVID-19, coronavirus disease 2019; IGHV, immunoglobulin heavy chain variable. |
During the 63rd ASH Annual Meeting and Exposition, Yun Choi, et al. reported data from a multicenter retrospective review of COVID-19 outcomes in 519 patients with lymphoid malignancies, including CLL; the review aimed to determine the odds ratio (OR) of deaths, severe events, and hospital admissions in patients with lymphoid malignancies diagnosed with COVID-19.3
The median age of patients in this study was 61.9 years, and the risks of death, severe event, and hospital admission increased with age: for each 10 years of age increase, the ORs were 1.78, 1.58, and 1.65, respectively. Patients with CLL had a greater risk of severe events (OR, 4.64), mortality (OR, 4.65) and hospital admission (OR, 5.93) compared with patients with HL.3
Patients who were in remission at the time of COVID-19 infection had a reduced risk of severe events (OR, 0.42), mortality (OR, 0.36), and hospital admission (OR, 0.40) compared to with active disease, while patients who were administered cytotoxic chemotherapy within 28 days of COVID-19 infection had a higher risk of severe events (OR, 2.54), mortality (OR, 2.79), and hospital admission (OR, 2.31). Patients who were administered an anti-CD20 monoclonal antibody within six months of COVID-19 infection also had a greater risk of severe events (OR, 2.60), mortality (OR, 2.17), and hospital admission (OR, 3.28) compared to those who did not.3
Patients with CLL may have suboptimal response after two COVID-19 vaccine doses. While the novel BNT162b2 mRNA COVID-19 vaccine was introduced with 95% efficacy in the immunocompetent, approximately 50% of patients with CLL are unable to achieve a humoral response to the vaccine, as detected by low anti-spike antibodies. Information regarding T-cell immune responses to the COVID-19 vaccines, however, is sparse. During the 63rd ASH Annual Meeting and Exposition, Cristina Bagacean, et al.4 and Gilad Itchaki, et al.5 presented data regarding the humoral and cellular responses, respectively, to COVID-19 vaccination in patients with CLL.
Humoral responses (Bagacean, et al.)
Bagacean, et al. investigated humoral responses in 530 patients with CLL (and 14 controls) following the first, second and third doses of the NBT162b2 and mRNA-1273 vaccines. The median age of the CLL patients was 71 years.4
Following the first dose, the global response rate was 27% (43/158).
Following the second dose, the global response rate was 52% (256/506).
Patients who were seronegative following the second dose were allowed a third dose, after which the response rate was 42% (28/66).
There were 40 patients who had SARS-CoV-2 infection prior to vaccination, and these patients were analyzed independently. Interestingly, all 40 patients achieved seroconversion after infection and a single dose of the vaccine, despite 30% of patients having ongoing CLL treatment.
Cellular responses (Itchaki, et al.)
Gilad Itchaki and colleagues investigated T-cell responses in 83 patients with CLL at 139 days post administration of the second dose of vaccine; of these, 68 patients were eligible for the analysis. The median age was 68 years, and 65% of the patients were male. Most patients were Binet stage A or B and were TN (28%); 46% of patients were on therapy with either a BTK inhibitor (n = 17) or a venetoclax-based regimen (n = 13). In the 12-month period prior to vaccination, 13 patients had been treated with an anti-CD20 monoclonal antibody; 29 patients (42%) had received prior anti-CD20 therapy at any time.5
A total of 32% of patients (22/68) had a T-cell immune response to the vaccine which was highly correlated to the detection of anti-spike IgG antibodies at the time of the second dose (p = 0.0239) and at the time of T-cell testing (p = 0.048).
A cumulative illness rating score >6, and hypertension specifically, were significantly associated with a lower T-cell response on univariate analysis (p < 0.05). No significant differences were seen regarding age, gender, treatment, of T-cell subpopulation distribution according to flow cytometry.
In summary, the findings of Chatzikonstantinou, et al. suggest age, CLL-directed treatment, and cardiac failure were significant risk factors for OS and confer a worse prognosis. Untreated patients had a better chance of survival than those on treatment or recently treated. However, there were limitations in this study, including missing asymptomatic patients and the increased likelihood of capturing data from hospitalized and/or symptomatic patients.
Choi et al. found that patients with CLL and patients who received cytotoxic chemotherapy within 6 months or anti-CD20 monoclonal antibodies at any time are likely to have poor COVID-19 outcomes. Patients at a high risk for poor prognosis should be prioritized for studies that offer monoclonal antibody prophylaxis. Further studies are needed to deduce if a deficit in humoral immunity may lead to poor response to vaccination and a poor outcome.
Bagacean, et al. showed a double-dose mRNA vaccination had a humoral response in 52% of patients with CLL and concluded that the best immune response booster in this population was SARS-CoV-2 infection. This was due to the significant increase in anti-spike antibodies that was seen in all patients with CLL that had previous infection, after receiving a single dose of the vaccine. Similarly, Gilad Itchaki, et al. showed that the BNT162b2 mRNA COVID-19 vaccine can illicit an immune response in patients with CLL. However, all three trials concluded that larger studies are warranted to validate these results.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox